Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this follow-up study is to learn about long-term patient survival and graft function in highly sensitized patients who have received desensitization treatment with imlifidase or standard of care (SoC) in order to enable kidney transplantation in clinical study ConfIdeS (20-HMedIdeS-17, NCT04935177).
This is an observational follow-up study subsequent to the ConfIdeS study (20-HMedIdeS-17, NCT04935177) in highly sensitized patients who were randomized to imlifidase or SoC desensitization prior to kidney transplantation with a deceased donor graft, or, if SoC perioperative treatment has been deemed not appropriate, wait for a more immunologically compatible organ offer.
After the patients have given written informed consent to participate in the follow-up they will be included in the study and followed until 5 years after randomization in the ConfIdeS study.
Most of the assessments in this study are already part of the follow up within SoC for these patients. During the local clinic routine follow-up visits at year 2, 3 and 5 after randomization in the ConfIdeS study, information about patient survival, wait-list status, graft survival, kidney function, and health related quality of life will be evaluated.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Imlifidase administered in the ConfIdeS study |
| ||
| Best available treatment administered in the ConfIdeS study |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Imlifidase administered in the ConfIdeS study | Drug | Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc- fragment and efficiently neutralizes Fc-mediated activities of IgG. |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of patients alive and free of dialysis at 3 years | 3 years after randomization in the ConfIdeS study |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of patients alive and free of dialysis at 5 years | 5 years after randomization in the ConfIdeS study | |
| Proportion of patients alive at 3 and 5 years | 3 and 5 years after randomization in the ConfIdeS study |
Not provided
Inclusion Criteria:
Exclusion Criteria:
1. Inability by the judgement of the investigator to participate in the trial for any reason.
Not provided
Not provided
Not provided
Not provided
Patients who have participated in the clinical study ConfIdeS (20-HMedIdeS-17, NCT04935177)
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Therese Åkerfeldt | Hansa Biopharma AB | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Alabama at Birmingham (UAB) Hospital | Birmingham | Alabama | 35249 | United States | ||
| Cedars-Sinai Medical Center |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Best available treatment administered in the ConfIdeS study | Other | Institution-specific desensitization treatment prior to kidney transplantation in the ConfIdeS study OR remain on wait list for a more compatible organ offer if desensitization with institutional protocol is not appropriate |
|
| Graft failure-free survival rates at 3 and 5 years | Graft failure-free survival is defined as time from randomization to the fist of either graft failure or death | 3 and 5 years after randomization in the ConfIdeS study |
| Graft survival rates at 3 and 5 years | To be assessed in patients who were transplanted at randomization in the ConfIdeS study | 3 and 5 years after randomization in the ConfIdeS study |
| Number of patients per wait-list category | The different wait-list categories are: transplanted, active, temporary inactive, inactive, or deceased | 3 and 5 years after randomization in the ConfIdeS study |
| Mean estimated glomerular filtration rate (eGFR) at 3 and 5 years | eGFR is a measure of kidney function. eGFR will be calculated based on p-creatinine according to the modification of diet in renal disease (MDRD) equation. Kidney disease is characterised by a decreased eGFR value. eGFR will be set to zero, for randomized patients who do not undergo transplantation, lose their graft or die. | 3 and 5 years after randomization in the ConfIdeS study |
| Proportion of patients with biopsy- and serology confirmed antibody-mediated rejection (AMR) | 3 and 5 years after randomization in the ConfIdeS study |
| Proportion of patients with biopsy confirmed cell-mediated rejection | 3 and 5 years after randomization in the ConfIdeS study |
| Treatment of graft rejection episodes | Any treatments given during rejection episodes will be recorded | 3 and 5 years after randomization in the ConfIdeS study |
| Los Angeles |
| California |
| 90048 |
| United States |
| Northwestern University, Dept. General Surgery, Div. Transplantation | Chicago | Illinois | 60611 | United States |
| University of Chicago, Department of Surgery, Clinical Research Center | Chicago | Illinois | 60637 | United States |
| John Hopkins Hospital | Baltimore | Maryland | 21287 | United States |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | United States |
| Washington University School of Medicine | St Louis | Missouri | 63110 | United States |
| Cooperman Barnabas Medical Center | Livingston | New Jersey | 07039 | United States |
| New York University (NYU) Langone Transplant Institute, NYU Langone Health | New York | New York | 10016 | United States |
| Columbia University | New York | New York | 10032 | United States |
| Houston Methodist Hospital | Houston | Texas | 77030 | United States |
| Methodist Hospital Specialty and Transplant | San Antonio | Texas | 78229 | United States |
| University of Washington Medical Center | Seattle | Washington | 98195 | United States |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | United States |